ArsenalBio Refocuses on In-Vivo CAR-T and Reduces Workforce
ArsenalBio is shifting its primary focus from clinical autologous solid-tumor cell therapies to in-vivo CAR-T programs spanning hematologic malignancies, autoimmunity and other chronic disease. The private company disclosed a substantial workforce reduction, retaining a…
